Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 adjunctive therapy in adults with chronic complex regional pain syndrome
2018-004750-21Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in complex regional pain syndrome (CRPS) and Complex Regional Pain Syndrome Type 1 (CRPS-1) comparing TAK-935 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change in mean 24-hour pain intensity NPS from baseline to the end of Part A (Week 15). Started Apr 2019; status: completed.
02
Drugs
soticlestat
03
Conditions
complex regional pain syndrome (CRPS)Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on 2018-004750-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004750-21.